The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs
Open accessAbstract
Significance: Mesenchymal stem or stromal cells (MSCs) offer great promise as potential therapies for cancers and other diseases. However, applications of MSCs for cancer therapy are hindered by their protumor potential under certain conditions, considerable donor variations, and limited expandability. Here we report generation of induced pluripotent stem cells (iPSC)-derived MSCs with same tumor homing capacity but much less protumor potential using a modified protocol with high derivation efficiency. Starting from iPSCs with almost unlimited expandability, the protocol can be readily scaled up to provide huge amounts of MSCs with uniform biological properties for multicenter evaluation, large animal experiments, and potential clinical trial. Moreover, therapeutic transgenes can be inserted into safe-harbor loci of iPSCs before derivation of MSCs to eliminate insertional mutation and guarantee stable expression of transgenes during prolonged expansion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Self-citationLee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898
Self-citationMechanisms involved in the therapeutic properties of mesenchymal stem cells
da Silva Meirelles, L., Fontes, A. M., Covas, D. T., & Caplan, A. I. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.10.002 · Cited by 1,436 · cited 1×
“Because of their potential for differentiation (10, 11) and production of immunomodulatory, angiogenic, anti-apoptotic, anti-scarring, and prosurvival factors (12), MSCs have shown promising regeneration potential after radical cancer treatment in animal models, such as soft tissue reconstruction after disfiguring sur…”
BackgroundFeeder-independent culture of human embryonic stem cells
Ludwig, T. E., Bergendahl, V., Levenstein, M. E., Yu, J., Probasco, M. D., & Thomson, J. A. (2006) · Nature Methods · doi:10.1038/nmeth902 · Cited by 681 · cited 2×
“modified the differentiation protocol by initially inhibiting Smad2/3 signaling in iPSCs cultured with chemically defined mTeSR1 medium (28) and then passaging cells by trypsinization (31) repeatedly (30) in 7.”
MethodMesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417
Kidd, S., Spaeth, E., Watson, K., Burks, J., Lu, H., Klopp, A., Andreeff, M., & Marini, F. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030563 · Cited by 371
Chaturvedi, P., Gilkes, D. M., Wong, C. C. L., Kshitiz, K., Luo, W., Zhang, H., Wei, H., Takano, N., Schito, L., Levchenko, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69244 · Cited by 181
Klopp, A. H., Zhang, Y., Solley, T., Amaya-Manzanares, F., Marini, F., Andreeff, M., Debeb, B., Woodward, W., Schmandt, R., Broaddus, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1916 · Cited by 178
Mesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168 · cited 1×
“T use of mesenchymal stromal or stem cells (MSCs) in cancer patients or cancer survivors is a promising strategy to improve treatment of advanced cancer (1) and to repair tissues damaged by cancers or by radical cancer therapies (2).”
BackgroundRegenerative therapy after cancer: what are the risks?
Donnenberg, V. S., Zimmerlin, L., Rubin, J. P., & Donnenberg, A. D. (2010) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2010.0352 · Cited by 95
Research works printed but not linked: 40
- 10.18632/oncotarget.1040 · DOI
- 10.1016/j.ccr.2011.01.020 · DOI · Paper page
- 10.3109/14653249.2010.542457 · DOI
- 10.1038/ncomms2766 · DOI · Paper page
- 10.1111/j.1600-0722.2011.00895.x · doi:10.1111/j.1600-0722.2011.00895.x
- 10.1158/0008-5472.CAN-09-1865 · DOI · Paper page
- 10.1126/science.276.5309.71 · DOI · Paper page
- 10.1126/science.284.5411.143 · DOI · Paper page
- 10.1177/0022034510386374 · DOI
- 10.1016/j.biocel.2010.09.023 · DOI
- 10.1634/stemcells.2008-0139 · DOI
- 10.1002/stem.572 · DOI
- 10.1038/nature06188 · DOI · Paper page
- 10.1158/2159-8290.CD-12-0101 · DOI · Paper page
- 10.1158/0008-5472.CAN-10-0538 · DOI · Paper page
- 10.1016/j.jcyt.2013.03.005 · DOI · Paper page
- 10.1371/journal.pone.0052465 · DOI · Paper page
- 10.1089/ten.tea.2010.0085 · DOI
- 10.1089/scd.2013.0591 · DOI
- 10.1002/stem.569 · DOI
- 10.1007/978-1-60761-962-8_13 · doi:10.1007/978-1-60761-962-8_13
- 10.1007/978-1-60761-999-4_11 · doi:10.1007/978-1-60761-999-4_11
- 10.1634/stemcells.2006-0420 · DOI · Paper page
- 10.1158/0008-5472.CAN-13-0087 · DOI
- 10.1182/blood-2007-12-128702 · DOI · Paper page
- 10.1091/mbc.e07-02-0166 · DOI · Paper page
- 10.4161/cc.9.14.12371 · DOI
- 10.1073/pnas.90.13.6155 · DOI · Paper page
- 10.1002/stem.1251 · DOI
- 10.1016/j.bbrc.2013.05.013 · DOI
- 10.1016/S0002-9440(10)63847-3 · DOI · Paper page
- 10.1002/(SICI)1097-4652(199910)181:1<96::AID-JCP10>3.0.CO;2-I · DOI
- 10.1073/pnas.1206653109 · DOI · Paper page
- 10.1074/jbc.M313319200 · DOI · Paper page
- 10.1007/BF02618296 · DOI · Paper page
- 10.1002/stem.1103 · DOI
- 10.1073/pnas.1301190110 · DOI · Paper page
- 10.1182/blood-2010-12-328161 · DOI · Paper page
- 10.1089/scd.2009.0499 · DOI
- 10.1371/journal.pone.0015576 · DOI
Cited by
Challenges and advances in clinical applications of mesenchymal stromal cells
Zhou, T., Yuan, Z., Weng, J., Pei, D., Du, X., He, C., & Lai, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01037-x · Cited by 712
“This strategy could eliminate insertional mutation as well as guarantee stable expression of transgenes during prolonged expansion [128].”
BackgroundTherapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer
Weng, Z., Zhang, B., Wu, C., Yu, F., Han, B., Li, B., & Li, L. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01141-y · Cited by 405
Hofer, H. R., & Tuan, R. S. (2016) · Stem Cell Research & Therapy · doi:10.1186/s13287-016-0394-0 · Cited by 360
Mesenchymal Stromal/Stem Cells in Regenerative Medicine and Tissue Engineering
Fitzsimmons, R. E. B., Mazurek, M. S., Soos, A., & Simmons, C. A. (2018) · Stem Cells International · doi:10.1155/2018/8031718 · Cited by 358
Manufacturing of primed mesenchymal stromal cells for therapy
Yin, J. Q., Zhu, J., & Ankrum, J. A. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0325-8 · Cited by 343
Metadata
- Authors
- Zhao, Q., Gregory, C. A., Lee, R. H., Reger, R. L., Qin, L., Hai, B., Park, M. S., Yoon, N., Clough, B., McNeill, E., Prockop, D. J., & Liu, F.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2014-12-29
- Volume
- 112
- Issue
- 2
- Pages
- 530-535
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2106569604
- Cited by
- 164
- References
- 10
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs. https://app.cochat.ai/papers/10.1073/pnas.1423008112
- The paper
- Zhao, Q., Gregory, C. A., Lee, R. H., Reger, R. L., Qin, L., Hai, B., Park, M. S., Yoon, N., Clough, B., McNeill, E., Prockop, D. J., & Liu, F. (2015). MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1423008112
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.